In the open-label Phase I/II study, 67 patients with advanced pancreatic cancer were treated. Patients were 18 years of age and older with histologically confirmed metastatic adenocarcinoma of
Roche pharmaceuticals division’s sales increased 6% to CHF9.7bn from CHF9.2bn for the prior year period. Diagnostics division’s sales were CHF2.5bn, an increase of 7%, compared to CHF2.3bn for
Ceplene is approved in the EU for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission. The launch is being
Rezaltas is a combination drug featuring the Daiichi Sankyo-developed olmesartan medoxomil (Olmetec), a high-affinity ARB (angiotensin receptor blocker) and azelnidipine (Calblock), a long-acting CCB (calcium channel blocker) that
Five new products approved for commercial sale in Japan comprise three new medical entities; Nesina for treatment of type 2 diabetes, Rozerem for treatment of insomnia and anti-cancer
Protein Potential’s R&D program is focused on vaccine development. The company has ongoing projects targeting vaccines for infectious diseases like malaria and bioterrorism agents including anthrax. Protein Potential’s
Sandoz said that the regulatory approvals of these medicines, if achieved, would enable it to increase access to affordable, high-quality therapeutic alternatives for these increasingly prevalent diseases. The
Pixantrone is a new aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. The rapporteurs, who are assigned
The trial was designed to test the Immuron hyperimmune antibody product BioGard as adjunct therapy to support the immune system of HIV patients undergoing long-term treatment with anti-retroviral
Reportedly the contract valued at circa GBP1.5m. Work on the project is expected to begin shortly and GMP manufacturing is expected to complete in early 2012. Gordon Sherriff,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.